Altogether, despite the research efforts focused on understanding the molecular basis of sensitivity to EGFR inhibitors, the prevailing view is that an in-depth analysis of the molecular responses elicited by these compounds in glioma cells is still required. The gene discussed is EGFR; the disease is glioma.